Overview

A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
PH-797804 is a potent ant-inflammatory drug that may reduce the inflammation that is associated with COPD. PH-797804 will be dosed to patients with COPD to evaluate its potential safety and efficacy profile in COPD.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer